For the Treatment of Nocturnal Bruxism: A Randomized Controlled Clinical Trial
Monitoring Editor: Alexander Muacevic and John R Adler
Zaed Ghassan Shehri,1 Issam Alkhouri,1 Mohammad Y Hajeer,2 Ibrahim Haddad,3 and Mohamad Husam Abu Hawa1
Reference
(Ref ID): PMC9719743
Chosen Image filename: PMC9719743_Figure_02.jpg
Document structure and format:
I. Introduction
The research paper titled "Evaluation of the Efficacy of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle for the Treatment of Nocturnal Bruxism: A Randomized Controlled Clinical Trial" aims to determine the effectiveness of injecting a low dose of botulinum toxin type A into the masseter muscle for treating nocturnal bruxism. Nocturnal bruxism is a condition where patients experience non-functional teeth grinding and clenching while sleeping. The research objectives are to investigate if injecting 10 MU of BTXA into the masseter muscle can reduce muscular activity, thereby resulting in reduced muscle spasms and pain symptoms associated with nocturnal bruxism for a period of three months.
II. Methodology
The research design employed in the study is a parallel-group randomized controlled trial with 22 participants. The sample was divided into two groups: the Botox group (BO) - injected with 10 MU of BTXA, and the placebo group (PL) - received a sham intervention. The study was conducted at the Department of Oral and Maxillofacial Surgery, University of Damascus Faculty of Dentistry, Syria. Data was collected through pain perception assessments using visual analogue scales, and muscle activity recorded by electromyography (EMG). Statistical tests were conducted to analyze the data, and any limitations or assumptions of the study include a small sample size.
III. Results
The study found that injecting 10 MU of BTXA into the masseter muscle significantly reduced muscular activity in the muscle, leading to decreased muscle spasms and pain symptoms associated with nocturnal bruxism for about three months. However, the symptoms gradually relapsed after three months. The differences in perceived pain values between the Botox group and the placebo group before and after the injection were statistically significant. The differences in the EMG recorded values were also statistically significant between the two groups.
IV. Discussion
The research findings suggest that injecting 10 MU of BTXA into the masseter muscle can provide temporary relief for patients suffering from nocturnal bruxism. However, the effects are only consistent for three months before the symptoms relapse. The study's limitations include a small sample size, and future research can investigate the long-term effects and optimal dosages for this treatment.
V. Conclusion
In conclusion, the research paper titled "Evaluation of the Efficacy of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle for the Treatment of Nocturnal Bruxism: A Randomized Controlled Clinical Trial" highlights the effectiveness of injecting a low dose of botulinum toxin type A into the masseter muscle in reducing the symptoms of nocturnal bruxism. While the effects are temporary, this study provides valuable insights into potential treatment options for patients suffering from nocturnal bruxism.
Comments